#ASCO26: Celcuity plans another FDA filing after positive breast cancer readout

Celcuity at #ASCO2026 (Karen Weintraub for Endpoints News) June 2, 2026 08:01 AM EDT R&D Cel­cu­ity aims for broad FDA ap­proval af­ter pos­i­tive breast can­cer read­out Nicole DeFeudis Senior Reporter Cel­cu­ity said a com­bi­na­tion reg­i­men with its ex­per­i­men­tal drug geda­tolis­ib dou­bled pa­tients’ like­li­hood of sur­vival with­out dis­ease pro­gres­sion or death in a late-stage breast can­cer … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER